Hand-Foot-Mouth Disease Treatment
Hand-foot-mouth disease (HFMD) requires supportive care only, as it is a self-limiting viral illness that resolves in 7-10 days without specific antiviral therapy.
Primary Management Approach
HFMD is a benign, self-limited viral infection caused by enteroviruses (primarily Coxsackievirus A16 and Enterovirus A71) that predominantly affects children under 5 years of age 1. The cornerstone of management is symptomatic treatment and parental counseling 2.
Supportive Care Measures
- Pain management: Acetaminophen or ibuprofen for fever and oral discomfort
- Hydration: Encourage fluid intake; cold liquids may be better tolerated with oral lesions
- Soft diet: Avoid acidic, spicy, or salty foods that irritate oral lesions
- Isolation: Keep child home from daycare/school until fever resolves and lesions crust over to prevent transmission
What NOT to Do
Do not routinely prescribe antibiotics, steroids, or intravenous immunoglobulin (IVIG) for uncomplicated HFMD. A large retrospective study of 3,778 hospitalized cases found no significant advantage of using steroids or IVIG in mild cases, and their use was associated with longer hospital stays in severe cases 3. Despite Chinese national guidelines recommending these interventions, WHO and US-CDC guidelines do not support their routine use 3.
Monitoring for Severe Disease
While most cases are benign, early recognition of severe disease is critical, particularly in children under 3 years with EV-A71 infection 4. Watch for these red flags indicating potential deterioration:
- Persistent high fever (>39°C for >3 days)
- Neurological involvement: Myoclonus, tremors, ataxia, altered consciousness, seizures
- Respiratory distress: Tachypnea, irregular breathing patterns
- Circulatory dysfunction: Tachycardia, cold extremities, prolonged capillary refill
- Laboratory abnormalities: Elevated WBC, hyperglycemia, elevated lactate
Children with these features require immediate hospitalization for intensive monitoring and treatment 4.
Emerging Treatment Options
Investigational Therapies
Recent research suggests EPs® 7630 (Pelargonium sidoides extract) may reduce disease duration and symptom severity. A 2024 randomized trial of 208 children showed significantly shorter disease duration (6.1 vs 8.6 days) and lower hospitalization rates with good safety profile 5. However, this requires validation before routine recommendation.
Valacyclovir showed dramatic improvement in one adult case report, with resolution within 48 hours 6, but this is insufficient evidence for routine use.
What About Antivirals?
Currently, no antiviral agents are approved for HFMD treatment 1. Drugs like ribavirin, suramin, and others remain investigational. Acyclovir/valacyclovir are not standard therapy despite isolated case reports.
Common Pitfalls to Avoid
- Over-medicalization: Most cases need only reassurance and symptomatic care 2
- Inappropriate antibiotic use: HFMD is viral; antibiotics are not indicated
- Premature discharge: Ensure parents understand warning signs before sending home
- Missing severe cases: EV-A71 infections in young children require closer monitoring
Prevention
- Hand hygiene: Frequent handwashing with soap and water
- Disinfection: Clean contaminated surfaces and toys
- Isolation: Exclude infected children from group settings
- Vaccination: EV-A71 vaccines are available in some Asian countries but not universally licensed 1, 7
The key message for parents: HFMD is uncomfortable but self-limited, requiring active monitoring rather than aggressive medical intervention 2.